Cited by 23Gastrointestinal motility and disordersDiabetes Management and ResearchGastrointestinal Bleeding Diagnosis and Treatment

Diabetic gastroenteropathy: a pan-alimentary complication

Open access
Kornum, Ditte S., Krogh, Klaus, Keller, Jutta, Malagelada, Carolina, Drewes, Asbjørn M., Brock, Christina·2025·Diabetologia

Abstract

Autonomic neuropathy contributes to the pathophysiology of diabetic gastroenteropathy, which impacts the entire gastrointestinal tract alongside pancreatic and gallbladder functions. This is evident in the widespread morphological remodelling of the enteric nervous system, smooth muscle cells, interstitial cells of Cajal and vascular supply, causing pan-enteric motor, sensory and secretory disturbances. The gastrointestinal symptoms caused by these changes are often burdensome and non-specific and frequently coexist with poor glycaemic management and even malnutrition, impacting quality of life negatively. The Gastroparesis Cardinal Symptom Index and the Gastrointestinal Symptom Rating Scale are validated questionnaires for assessing gastrointestinal symptoms. However, clinical supplementary objective measures are essential. Transit time assessments are frequently used and typically evaluated using gastric emptying scintigraphy, breath tests or colonic radiopaque markers, but they cannot measure contractile activity or fluid transport. The primary treatment goals are to prevent further disease progression and to obtain symptomatic relief. Treatments include improved glycaemic management and dietary modifications, while pharmacological treatments target gastrointestinal symptoms, small intestinal bacterial overgrowth and exocrine pancreatic insufficiency. Invasive interventions may involve gastric peroral pyloromyotomy or the implantation of a gastric neurostimulator to manage pharmacologically refractory gastroparesis. This review describes the prevalence, pathophysiology, clinical presentation, assessment and treatment of diabetic gastrointestinal dysfunction within each segment of the gastrointestinal tract and directly connected exocrine organs.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-025-06365-y

Cites

97 of 97 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The selective 5‐HT4 receptor agonist prucalopride may improve nausea, early satiety, bloating, and quality of life in selected patients, though it carries gastrointestinal side effects and requires individualization.

    “The selective 5‑HT4 receptor agonist prucalopride may improve nausea, early satiety, bloating, and quality of life in selected patients, though it carries gastrointestinal side effects and requires individualization [49, 124, 125].”

    From Diabetic gastroparesis: pathophysiology and impact on insulin timing choices (2026) · cites this paper as [49]

    Table 1 (Gastric complications of diabetes; page not provided) identifies prucalopride as a 5-HT4 receptor agonist, reports improved quality of life in chronic idiopathic constipation, and lists abdominal pain, nausea and diarrhoea as side effects. The Colonic complications section says it may help constipated individuals with gastroparesis, while the Gastric complications section recommends individualised treatment generally. Neither passage says prucalopride improves nausea, early satiety or bloating. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kornum, D. S., Krogh, K., Keller, J., Malagelada, C., Drewes, A. M., & Brock, C.
Affiliations
  • Aarhus University (DK)
  • Universität Hamburg (DE)
  • Universitat Autònoma de Barcelona (ES)
  • Aalborg University Hospital (DK)
Corresponding author
Brock, Christina
Venue
Diabetologia
Published
2025-02-11
Volume
68
Issue
5
Pages
905-919
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W4407356611
Cited by
23
References
97
Citations by year
2026: 15 · 2025: 8
FWCI
5.47
Type
journal article
Language
en
Open access
Locations
  • Diabetologia (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • VBN Forskningsportal (Aalborg Universitet) (submittedVersion, cc-by-nc-nd)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal Bleeding Diagnosis and Treatment
Keywords
autonomic neuropathy, interstitial cells of Cajal, gastrointestinal motility disorders, gastric emptying, small intestinal bacterial overgrowth, exocrine pancreatic insufficiency, gastroparesis, glycemic control, malnutrition, quality of life
MeSH terms
Diabetic Neuropathies, Gastric Emptying, Gastrointestinal Diseases, Humans, Gastroparesis, Diabetes Complications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review